series-c-plus
Stage
3
Investors
About
Medasense develops medical devices and AI-based monitoring technology to quantify nociception (the physiological response to pain) in patients who cannot communicate. Its PMD-200 monitor uses NOL (Nociception Level) technology for intraoperative and critical care pain assessment.
Explore Medasense's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.